Circulate Health brings longevity-focused plasma exchange to London

The procedure involves separating blood plasma from whole blood and replacing it with a substitute fluid. While TPE is an established medical practice, Circulate Health has standardized the process within a longevity-focused framework. The company, founded on research from the Buck Institute for Research on Aging, leverages multi-omic and epigenetic analysis to track the treatment's impact on systemic inflammation and glycan patterns.

Faye Mythen, consulting CEO at Reborne, noted that the collaboration aims to apply rigorous scientific standards to the emerging field of longevity. The partnership offers a shift from traditional disease treatment toward preventive care, emphasizing the extension of healthspan—the duration of life spent in optimal physical and cognitive condition.

Backed by a $12 million seed round led by Khosla Ventures, Circulate Health has already published peer-reviewed findings in journals such as Aging Cell. By bringing these clinical operations to Marylebone, Reborne aims to provide patients with access to interventions that have shown measurable effects on biological age in recent human trials. The expansion reflects a broader industry movement to translate geroscience research into structured, physician-led clinical environments.